Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

The Lancet

Volumn 390, Issue 10101, 2017, Pages 1499-1510

  Margolis, David A ^a   Gonzalez Garcia, Juan ^b   Stellbrink, Hans Jürgen ^c   Eron, Joseph J ^d   Yazdanpanah, Yazdan ^e   Podzamczer, Daniel ^f   Lutz, Thomas ^g   Angel, Jonathan B ^h   Richmond, Gary J ⁱ   Clotet, Bonaventura ^j   Gutierrez, Felix ^k   Sloan, Louis ^l   Clair, Marty St ^a   Murray, Miranda ^a   Ford, Susan L ^m   Mrus, Joseph ^a   Patel, Parul ^a   Crauwels, Herta ⁿ   Griffith, Sandy K ^a   Sutton, Kenneth C ^a   Dorey, David ^o   Smith, Kimberly Y ^a   Williams, Peter E ⁿ   Spreen, William R ^a   more..

^a VIIV HEALTHCARE   (United States)

^b HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^c Infektionsmedizinisches Centrum Hamburg   (Germany)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e BICHAT HOSPITAL   (France)

^f HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^g Infektiologikum   (Germany)

^h UNIVERSITY OF OTTAWA   (Canada)

ⁱ Broward General Medical Center   (United States)

^j HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^k HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^l North Texas Infectious Diseases Consultants   (United States)

^m GLAXOSMITHKLINE   (United States)

ⁿ JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^o GLAXOSMITHKLINE   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; CABOTEGRAVIR; RILPIVIRINE; VIRUS RNA; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ABACAVIR, LAMIVUDINE DRUG COMBINATION; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LAMIVUDINE; PYRIDONE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BRONCHITIS; CD4 LYMPHOCYTE COUNT; CONDYLOMA ACUMINATUM; CONTROLLED STUDY; COUGHING; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FEMALE; FEVER; GASTROENTERITIS; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFLUENZA; INJECTION SITE CONTUSION; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE NODULE; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; INJECTION SITE WARMTH; INSOMNIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; RHINOPHARYNGITIS; SYPHILIS; UPPER RESPIRATORY TRACT INFECTION; CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECT; GLOBAL HEALTH; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAMUSCULAR DRUG ADMINISTRATION; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; DIDEOXYNUCLEOSIDES; DRUG COMBINATIONS; FEMALE; GLOBAL HEALTH; HIV INFECTIONS; HIV-1; HUMANS; INJECTIONS, INTRAMUSCULAR; LAMIVUDINE; MALE; PYRIDONES; REVERSE TRANSCRIPTASE INHIBITORS; RILPIVIRINE; VIRAL LOAD;

EID: 85025426676     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)31917-7     Document Type: Article

References (24)

1. WHO. Progress report 2016: prevent HIV, test and treat all, 2016, World Health Organization, Geneva http://www.who.int/hiv/pub/progressreports/2016-progress-report/en/ (accessed June 20, 2017).
2. Walensky, RP, Paltiel, AD, Losina, E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 194 (2006), 11–19.
3. Blanc, FX, Sok, T, Laureillard, D, et al., for the CAMELIA (ANRS 1295-CIPRA KH001) Study Team. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 365 (2011), 1471–1481.
4. Glass, T, Cavassini, M, Asking about adherence: from flipping the coin to strong evidence. Swiss Med Wkly, 144, 2014, w14016.
5. Margolis, DA, Boffito, M, Long-acting antiviral agents for HIV treatment. Curr Opin HIV AIDS 10 (2015), 246–252.
6. Karmon, SL, Mohri, H, Spreen, W, Markowitz, M, GSK1265744 demonstrates robust in vitro activity against various clades of HIV-1. J Acquir Immune Defic Syndr 68 (2015), e39–e41.
7. Spreen, W, Min, S, Ford, SL, et al. Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor. HIV Clin Trials 14 (2013), 192–203.
8. Ford, SL, Gould, E, Chen, S, et al. Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744. Antimicrob Agents Chemother 57 (2013), 5472–5477.
9. Spreen, WR, Margolis, DA, Pottage, JCJ, Long-acting injectable antiretrovirals for HIV treatment and prevention. Curr Opin HIV AIDS 8 (2013), 565–571.
10. Edurant (package insert), 2015, Janssen Therapeutics, Titusville, NJ.
11. Odefsey (package insert), 2016, Gilead Sciences, Inc, Foster City, CA.
12. Williams, PE, Crauwels, HM, Basstanie, ED, Formulation and pharmacology of long-acting rilpivirine. Curr Opin HIV AIDS 10 (2015), 233–238.
13. Margolis, DA, Brinson, CC, Smith, GH, et al., for the LAI116482 Study Team. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. Lancet Infect Dis 15 (2015), 1145–1155.
14. Trezza, C, Ford, SL, Spreen, W, Pan, R, Piscitelli, S, Formulation and pharmacology of long-acting cabotegravir. Curr Opin HIV AIDS 10 (2015), 239–245.
15. Spreen, W, Ford, SL, Chen, S, et al. GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects. J Acquir Immune Defic Syndr 67 (2014), 481–486.
16. Spreen, W, Williams, P, Margolis, D, et al. Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults. J Acquir Immune Defic Syndr 67 (2014), 487–492.
17. DAIDS Regulatory Support Center. Division of AIDS table for grading the severity of adult and pediatric adverse events. https://rsc.tech-res.com/docs/default-source/safety/daids_ae_grading_table_v2_nov2014.pdf?sfvrsn=8 (accessed June 1, 2017).
18. Bolstad, WM, Curran, JM, Introduction to Bayesian statistics, 3rd edn., 2017, John Wiley & Sons, Hoboken, NJ.
19. Palella, FJJ, Fisher, M, Tebas, P, et al. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants. AIDS 28 (2014), 335–344.
20. Arribas, JR, Pialoux, G, Gathe, J, et al. Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial. Lancet Infect Dis 14 (2014), 581–589.
21. Trottier, B, Lake, JE, Logue, K, et al. Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, phase IIIb study. Antivir Ther, 2017 published online April 12. DOI:10.3851/IMP3166.
22. Wensing, AM, Calvez, V, Günthard, HF, et al. 2015 Update of the drug resistance mutations in HIV-1. Top Antivir Med 23 (2015), 132–141.
23. Mobula, L, Barnhart, M, Malati, C, et al. Long-acting, injectable antiretroviral therapy for the management of HIV infection: an update on a potential game-changer. J AIDS Clin Res 6 (2015), 1–5.
24. Dolgin, E, Long-acting HIV drugs advanced to overcome adherence challenge. Nat Med 20 (2014), 323–324.